BioWa, Inc. and Lonza have entered into a research agreement with Pfizer for the use of their POTELLIGENT CHOK1SV cell line in the R&D of multiple antibodies in Pfizer’s pipeline. POTELLIGENT CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation POTELLIGENT technology with Lonza’s GS Gene Expression System, which includes the host cell line, CHOK1SV.

“We are pleased that the core value of POTELLIGENT Technology has been recognized by a global pharmaceutical company such as Pfizer, and are excited to work together with Pfizer on their innovative antibody research pipelines.” said Yasunori Yamaguchi, Ph.D., president and chief executive officer of BioWa.

“The GS System and the CHOK1SV Cell Line continue to be a gold standard for therapeutic antibody development. We are proud to be able to support Pfizer with this technology for their ongoing development portfolio.” said Karen Fallen, vice president, head of licensing, Lonza Custom Development Services.